Helping premature infants thrive.
Vernx Biotechnology aims to be the global leader in commercialising nutritional products aimed at reducing necrotising enterocolitis and other gut disorders in premature infants. Vernx will be the first company in the APAC region to sell human donor milk and human milk fortifier to hospitals. In addition we will commercialise a novel fatty acid to help improve gut disease in premature infants. Vernx is owned by the two founders.